- Home
- BY vs GERN Comparison
BY vs GERN Comparison
Compare BY & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BY
- GERN
- Stock Information
- Founded
- BY 1914
- GERN 1990
- Country
- BY United States
- GERN United States
- Employees
- BY N/A
- GERN N/A
- Industry
- BY Major Banks
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- BY Finance
- GERN Health Care
- Exchange
- BY Nasdaq
- GERN Nasdaq
- Market Cap
- BY 1.2B
- GERN 974.5M
- IPO Year
- BY 2017
- GERN 1996
- Fundamental
- Price
- BY $28.20
- GERN $1.39
- Analyst Decision
- BY Hold
- GERN Buy
- Analyst Count
- BY 3
- GERN 7
- Target Price
- BY $33.67
- GERN $4.17
- AVG Volume (30 Days)
- BY 358.6K
- GERN 9.4M
- Earning Date
- BY 07-24-2025
- GERN 08-07-2025
- Dividend Yield
- BY 1.43%
- GERN N/A
- EPS Growth
- BY N/A
- GERN N/A
- EPS
- BY 2.69
- GERN N/A
- Revenue
- BY $379,386,000.00
- GERN $116,293,000.00
- Revenue This Year
- BY $16.23
- GERN $160.12
- Revenue Next Year
- BY $3.79
- GERN $55.01
- P/E Ratio
- BY $10.42
- GERN N/A
- Revenue Growth
- BY 3.48
- GERN 22264.04
- 52 Week Low
- BY $22.63
- GERN $1.17
- 52 Week High
- BY $32.89
- GERN $5.06
- Technical
- Relative Strength Index (RSI)
- BY 68.08
- GERN 42.89
- Support Level
- BY $26.54
- GERN $1.34
- Resistance Level
- BY $26.03
- GERN $1.57
- Average True Range (ATR)
- BY 0.55
- GERN 0.10
- MACD
- BY 0.31
- GERN -0.02
- Stochastic Oscillator
- BY 87.86
- GERN 12.50
About BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.